Keystone Investors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$10.3M Buy
9,560
+4,360
+84% +$4.17M 0.92% 25
2025
Q3
$3.97M Buy
+5,200
New +$3.87M 0.46% 43
2025
Q2
Sell
-26,456
Closed -$21.9M 60
2025
Q1
$21.9M Buy
26,456
+12,523
+90% +$10.4M 3.07% 12
2024
Q4
$10.8M Buy
13,933
+13,140
+1,657% +$10.9M 0.75% 25
2024
Q3
$703K Buy
+793
New +$713K 0.05% 56
2024
Q1
Sell
-73,399
Closed -$42.8M 79
2023
Q4
$42.8M Buy
73,399
+18,799
+34% +$11M 3.61% 10
2023
Q3
$29.3M Buy
+54,600
New +$28.1M 3.49% 11

Other funds holding LLY

Keystone Investors's LLY Position: Q4 2025 in Review

Keystone Investors increased its Eli Lilly (LLY) stake by 84% in Q4 2025, buying an estimated $4.17M and bringing the position to 9,560 shares worth $10.3M. The position accounts for 0.92% of the portfolio, ranked #25.

Keystone Investors first reported a position in LLY in Q3 2023 and has held it in 7 quarters since. The position peaked at $42.8M in Q4 2023. 4,428 funds tracked by Wall St. Rank hold LLY as of Q4 2025.

  • Keystone Investors held 9,560 shares of Eli Lilly worth $10.3M as of Q4 2025.
  • Keystone Investors bought 4,360 Eli Lilly shares in Q4 2025, an estimated $4.17M.
  • Eli Lilly made up 0.92% of Keystone Investors's portfolio in Q4 2025, its #25 holding.
  • Keystone Investors first reported a position in Eli Lilly in Q3 2023 and has held it in 7 quarters since.
  • Keystone Investors's Eli Lilly position peaked at $42.8M in Q4 2023.
  • 4,428 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2025.

Based on Keystone Investors's 13F filing for Q4 2025, filed 13 Feb 2026.